L. Gillen

发表

Effect of Multiple Doses of Rifampin on the [14C N‐methyl] Erythromycin Breath Test in Healthy Male Volunteers

S. Waldman, J. Schwartz, J. Schwartz, 1998, Journal of clinical pharmacology.

A New Cyclooxygenase‐2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low‐Dose Aspirin in Healthy Volunteers

S. Waldman, H. Greenberg, K. Gottesdiener, 2000, Journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Tepoxalin after Single Oral Dose Administration to Healthy Volunteers

I. L. Smith, S. Waldman, T. Bjornsson, 1996, Journal of clinical pharmacology.

Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity

S. Waldman, B. Gertz, T. Prueksaritanont, 1999, Journal of clinical pharmacology.

Antiplatelet Effects of MK‐852, a Platelet Fibrinogen Receptor Antagonist, in Healthy Volunteers

T. Bjornsson, H. Greenberg, M. Goldberg, 2000, Journal of clinical pharmacology.

Simvastatin Does Not Affect CYP3A Activity, Quantified by the Erythromycin Breath Test and Oral Midazolam Pharmacokinetics, in Healthy Male Subjects

S. Waldman, H. Greenberg, T. Prueksaritanont, 2000, Journal of clinical pharmacology.

Exposure‐Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice

W. Hauck, S. Waldman, H. Greenberg, 2003, Journal of clinical pharmacology.

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E‐3174

L Gillen, S. Waldman, T. Rushmore, 1999, Clinical pharmacology and therapeutics.

Effect of Mibefradil on CYP3A4 In Vivo

W. Hauck, S. Waldman, H. Greenberg, 2003, Journal of clinical pharmacology.

MK‐0966, a cyclooxygenase‐2 (COX‐2) specific inhibitor, had no effect on the anti‐platelet activity of low‐dose aspirin (ASA) measured by serum thromboxane B2 (TXB2) production and platelet aggregation

H. Greenberg, M. Huntington, P. Wong, 1999 .